A kinase-independent function of AKT promotes cancer cell survival
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The serine–threonine kinase AKT regulates proliferation and survival by phosphorylating a network of protein substrates. In this study, we describe a kinase-independent function of AKT. In cancer cells harboring gain-of-function alterations in MET, HER2, or Phosphatidyl-Inositol-3-Kinase (PI3K), catalytically inactive AKT (K179M) protected from drug induced cell death in a PH-domain dependent manner. An AKT kinase domain mutant found in human melanoma (G161V) lacked enzymatic activity in vitro and in AKT1/AKT2 double knockout cells, but promoted growth factor independent survival of primary human melanocytes. ATP-competitive AKT inhibitors failed to block the kinase-independent function of AKT, a liability that limits their effectiveness compared to allosteric AKT inhibitors. Our results broaden the current view of AKT function and have important implications for the development of AKT inhibitors for cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
The nuts and bolts of AGC protein kinases
Pearce, L. R., Komander, D., & Alessi, D. R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2822 · Cited by 1,294 · cited 1×
“The serine–threonine kinase AKT is a non-receptor kinase that plays critical roles in growth and metabolism (Pearce et al., 2010).”
BackgroundAKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967 · cited 2×
“We could not explain these results by differential effects on induction of ErbB3 expression or IGF-IRβ phosphorylation (Figure 1—figure supplement 9) which can accompany AKT inhibition and mediate resistance to AKT inhibitors (Chandarlapaty et al., 2011).”
Background
Research works printed but not linked: 21
- Arita, 1992, Growth of human melanocyte cultures supported by 12-O-tetradecanoylphorbol-13-acetate is mediated through protein kinase C activation, Cancer Research, 52, 4514
- Barretina, 2012, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, 483, 603, 10.1038/nature11003 · DOI · Paper page
- Calleja, 2009, Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition, PLOS Biology, 7, e17, 10.1371/journal.pbio.1000017 · DOI · Paper page
- Carpten, 2007, A transforming mutation in the pleckstrin homology domain of AKT1 in cancer, Nature, 448, 439, 10.1038/nature05933 · DOI · Paper page
- Chan, 2011, Resistance of Akt kinases to dephosphorylation through ATP-dependent conformational plasticity, Proceedings of the National Academy of Sciences of USA, 108, E1120, 10.1073/pnas.1109879108 · DOI
- Engelman, 2005, ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines, Proceedings of the National Academy of Sciences of USA, 102, 3788, 10.1073/pnas.0409773102 · DOI · Paper page
- Ericson, 2010, Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation, Proceedings of the National Academy of Sciences of USA, 107, 2598, 10.1073/pnas.0914018107 · DOI · Paper page
- Franke, 1995, The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase, Cell, 81, 727, 10.1016/0092-8674(95)90534-0 · DOI · Paper page
- Gherardi, 2012, Targeting MET in cancer: rationale and progress, Nature Reviews Cancer, 12, 89, 10.1038/nrc3205 · DOI · Paper page
- Green, 2008, Use of Akt inhibitor and a drug-resistant mutant validates a critical role for protein kinase B/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake, The Journal of Biological Chemistry, 283, 27653, 10.1074/jbc.M802623200 · DOI
- Heerding, 2008, Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H- imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase, Journal of Medicinal Chemistry, 51, 5663, 10.1021/jm8004527 · DOI · Paper page
- Hirai, 2010, MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo, Molecular Cancer Therapeutics, 9, 1956, 10.1158/1535-7163.MCT-09-1012 · DOI · Paper page
- Landgraf, 2008, Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain, Biochemistry, 47, 12260, 10.1021/bi801683k · DOI · Paper page
- Lin, 2013, Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models, Clinical Cancer Research, 19, 1760, 10.1158/1078-0432.CCR-12-3072 · DOI · Paper page
- Okuzumi, 2009, Inhibitor hijacking of Akt activation, Nature Chemical Biology, 5, 484, 10.1038/nchembio.183 · DOI · Paper page
- Parikh, 2012, Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers, Proceedings of the National Academy of Sciences of USA, 109, 19368, 10.1073/pnas.1204384109 · DOI · Paper page
- Rhodes, 2008, Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity, Cancer Research, 68, 2366, 10.1158/0008-5472.CAN-07-5783 · DOI · Paper page
- She, 2008, Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling, PLOS ONE, 3, e3065, 10.1371/journal.pone.0003065 · DOI · Paper page
- Stephens, 1998, Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B, Science, 279, 710, 10.1126/science.279.5351.710 · DOI · Paper page
- Thomas, 2002, High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate, Current Biology, 12, 1256, 10.1016/S0960-9822(02)00972-7 · DOI · Paper page
- Wu, 2010, Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition, PLOS ONE, 5, e12913, 10.1371/journal.pone.0012913 · DOI · Paper page
Cited by
AKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
Alzahrani, A. S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.009 · Cited by 1,054
Chemoproteomics and Chemical Probes for Target Discovery
Drewes, G., & Knapp, S. (2018) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.06.008 · Cited by 132
Discovery of a small-molecule inhibitor of specific serine residue BAD phosphorylation
Pandey, V., Wang, B., Mohan, C. D., Raquib, A. R., Rangappa, S., Srinivasa, V., Fuchs, J. E., Girish, K. S., Zhu, T., Bender, A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1804897115 · Cited by 59
A critical evaluation of the approaches to targeted protein degradation for drug discovery
Chopra, R., Sadok, A., & Collins, I. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.02.002 · Cited by 53
Lrp4 domains differentially regulate limb/brain development and synaptic plasticity
Pohlkamp, T., Durakoglugil, M., Lane-Donovan, C., Xian, X., Johnson, E. B., Hammer, R. E., & Herz, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116701 · Cited by 28
Inhibitors of AKT kinase increase LDL receptor mRNA expression by two different mechanisms
Bjune, K., Wierød, L., & Naderi, S. (2019) · PLOS ONE · doi:10.1371/journal.pone.0218537 · Cited by 8
Metadata
- Authors
- Vivanco, I., Chen, Z. C., Tanos, B., Oldrini, B., Hsieh, W.-Y., Yannuzzi, N., Campos, C., & Mellinghoff, I. K.
- Venue
- eLife
- Publisher
- eLife Sciences Publications, Ltd
- Published
- 2014-12-31
- Volume
- 3
- ISSN
- 2050-084X (ISSN-L)
- OpenAlex
- W2129181865
- Cited by
- 87
- References
- 3
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0/ (vor)
- creativecommons.org/licenses/by/4.0/ (am)
- creativecommons.org/licenses/by/4.0/ (tdm)
- Funders
- National Institutes of Health (1R01NS080944–01, U54CA143798, F32 GM096558)
- James S. McDonnell Foundation
- National Brain Tumor Society
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.